论文信息 - Characterisation of a mitochondrial glutamine transporter provides a new opportunity for targeting glutamine metabolism in acute myeloid leukaemia. - 字舞流文

Characterisation of a mitochondrial glutamine transporter provides a new opportunity for targeting glutamine metabolism in acute myeloid leukaemia.

F. Dernie | Francesco Dernie

[1] H. Lee,et al. A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells. , 2019, Cell metabolism.

[2] Shiyong Li,et al. Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression , 2019, Nature Metabolism.

[3] L. di Lisio,et al. Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. , 2018, Blood.

[4] T. Kickler. The delectability of platelets to a phagocyte. , 2018, Blood.

[5] A. D’Alessandro,et al. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. , 2017, Experimental hematology.

[6] M. Carroll,et al. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. , 2017, Cancer discovery.

[7] J. Velez,et al. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes , 2016, Oncotarget.

[8] S. Demo,et al. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. , 2015, Blood.

[9] J. Gribben,et al. HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress. , 2013, Cell stem cell.